enquiry@pharmascroll.com
Mail Us
-
Recent MS survey, sponsored by Celgene, highlights useful patient insights
- October 16, 2018
- Posted by: Pharmascroll
No CommentsA survey from the Multiple Sclerosis Association of America (MSAA), sponsored by Celgene, showed people with multiple sclerosis are worried about brain volume loss and want more information. About Pharmascroll: Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease
-
Spectramax light therapy can be a potential treatment for Parkinson’s disease
- October 14, 2018
- Posted by: Pharmascroll
As per a recent study conducted and presented in International Parkinson and Movement Disorder Society Congress, Once-daily Spectramax™ LT is associated with a trend in improving PD symptom severity, and improvements of non-motor symptoms and quality of life. The study was conducted with an aim to evaluate the safety and effectiveness of Spectramax™ specialized bandwidth
-
Brain antioxidant levels can detect progression of Alzheimer’s Disease, study states
- October 14, 2018
- Posted by: Pharmascroll
In a breakthrough human study, published in Eureka Alert, anti-oxidant, glutathione (GSH), which protects the brain from stress, has been found to be significantly depleted in Alzheimer’s patients compared to normal subjects. As GSH is a very important anti-oxidant that protects the brain from free radicals, the findings give us another measure to use when
-
FDA approves Galcanezumab (Emgality) for Preventive Migraine Treatment
- October 8, 2018
- Posted by: Pharmascroll
Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults. Emgality offers a once-monthly, self-administered, subcutaneous injection. Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients. Emgality will be available
-
Smartphones can be used to detect Parkinson’s symptoms early, research says
- October 8, 2018
- Posted by: Pharmascroll
As per a latest research conducted in University of Oxford, smartphones can be used to detect the Parkinson’s symptoms. Oxford Mathematician Siddharth Arora, in a latest article, talked about his and his colleagues’ research in to using smartphone technology to anticipate the symptoms of Parkinson’s disease. “Parkinson’s disease (PD) is the second most common neurodegenerative
-
Teva Announces AJOVY™ (fremanezumab) approval in the US market
- September 17, 2018
- Posted by: Pharmascroll
Teva announced that the U.S. Food and Drug Administration (FDA) has approved AJOVY (fremanezumab-vfrm) injection for the preventive treatment of migraine in adults. AJOVY, a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor, is the first and only anti-CGRP treatment for the prevention of migraine
-
Further evidence generated for Neurofilament light chain as MS biomarker
- September 7, 2018
- Posted by: Pharmascroll
As per a latest study results published in Dove Press, further clinical evidence has been generated to support the use of Neurofilament light chain as a biomarker for Multiple Sclerosis patients. There is a need for biomarkers in multiple sclerosis (MS) to make an early diagnosis and monitor its progression. This study was designed to
-
Xenon includes Phase 3 Ready molecule in pipeline for Epilepsy
- September 7, 2018
- Posted by: Pharmascroll
Xenon Pharmaceuticals reported the expansion of its ion channel product pipeline with XEN496 (active ingredient ezogabine), a Kv7 potassium channel modulator for the potential treatment of epilepsy. Based on feedback from the U.S. Food and Drug Administration (FDA), Xenon anticipates initiating a single, pivotal Phase 3 clinical trial in approximately mid-2019 examining XEN496’s efficacy as
-
Ibudilast shows benefits on slowing brain shrinkage in the latest trial results
- September 6, 2018
- Posted by: Pharmascroll
MediciNova announced that the New England Journal of Medicine has published results of the SPRINT-MS Phase 2b trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS). “These findings are significant for patients with progressive MS,” says Robert Fox, M.D., the study’s principal investigator and vice-chair for research in Cleveland Clinic’s Neurological Institute. “Our hope
-
Novel Biomarker for diagnosis of Alzheimer’s identified by researchers
- September 5, 2018
- Posted by: Pharmascroll
As per a latest study published and to be presented at AAN 2018, Semantic intrusion (SI) errors may highlight specific breakdowns in memory associated with preclinical Alzheimer disease (AD); however, there have been no investigations to determine whether SI errors occur with greater frequency in persons with amnestic mild cognitive impairment (aMCI) confirmed as amyloid